Science First: How the FDA Has the Blueprint to Safeguard Vaping

Enforcement actions alone—raids on stores or seizures at ports—cannot resolve a crisis that the FDA’s own policies have created.

A worker injects a pod with flavored oil for an e-cigarette company on the production line at one of China's leading manufacturers of vaping products, in Shenzhen, China, on Sept. 25, 2019. Kevin Frayer/Getty Images

Commentary

In a bureaucracy often criticized for its sluggish pace and overreach, Food and Drug Administration (FDA) Commissioner Marty Makary is proving what a science-first approach can achieve.